GlassScriptPhysician profile
Sabina Braude
NPI 1386891638
$2,454.28
in general payments reported to CMS, 2019-2025
18 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $85.17 · 2021: $261 · 2022: $433 · 2023: $475 · 2024: $483 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,032.68 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.05 | 2020-2024 | Xifaxan, Plenvu |
| Glaxosmithkline, LLC. | $167.17 | 2019 | |
| Celgene Corporation | $165.12 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $135.30 | 2025 | Rezdiffra |
| Pfizer INC. | $116.32 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2022 | |
| Boston Scientific Corporation | $91.93 | 2023 | Apollo Esg System |
| Janssen Biotech, INC. | $87.78 | 2023-2024 | Stelara, Simponi Aria, Simponi |
| Qol Medical, LLC | $65.95 | 2021-2024 | Sucraid |
| Ardelyx, INC. | $56.13 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $47.68 | 2023-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $46.10 | 2021-2024 | Entyvio |
| Aimmune Therapeutics, INC. | $45.50 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $21.00 | 2023 | Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $14.66 | 2023 | |
| Fresenius Kabi USA, LLC | $14.62 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabina Braude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.